Clik here to view.
Amarantus eltoprazine PD data published
Amarantus BioSciences Holdings (OTCQB:AMBS) announced the publication of results of a Phase 2a study of eltoprazine in Parkinson’s disease levodopa-induced dyskinesias (PD-LID). The paper titled,...
View ArticleClik here to view.
Amarantus and Anavex in AD biomarker collaboration
Amarantus BioScience Holdings (OTCQB:AMBS) and Anavex Life Sciences (OTCQX:AVXL) have signed a biomarker services agreement in which Amarantus will evaluate the pharmacodynamic effect of ANAVEX 2-73...
View ArticleClik here to view.
Amarantus to present LymPro poster at AD/PD 2015
Amarantus BioSciences Holdings’ (OTCQB:AMBS) abstract titled, “The LymPro Assay: A Biomarker For Alzheimer’s Disease Using Blood Samples From Clinically Diagnosed Alzheimer’s Disease And Cognitively...
View ArticleClik here to view.
Amarantus to start Phase 2b with eltoprazine in PD
Amarantus BioScience Holdings (OTCQB:AMBS) has an active IND application with the neurology division of the FDA to start a Phase 2b program of eltoprazine for the treatment of Parkinson’s disease...
View ArticleClik here to view.
Amarantus presents positive data on MANF ocular effect
Amarantus BioScience Holdings (OTCQB:AMBS) has presented positive preclinical data for MANF (mesencephalic-astrocyte-derived neurotrophic factor) in retinitis pigmentosa (RP) at the Association for...
View ArticleClik here to view.
Amarantus posts blood-based data from MSPrecise
Amarantus BioScience Holdings (OTCQB:AMBS) has reported preliminary data from the blood-based version of its MSPrecise diagnostic test for multiple sclerosis. MSPrecise, a next-generation DNA...
View ArticleClik here to view.
Amarantus in cGMP pact with Catalent Biologics
Amarantus BioScience Holdings (OTCQB:AMBS) has entered into a manufacturing agreement with Catalent Pharma Solutions (NYSE:CTLT) for clinical-grade production of MANF (mesencephalic-astrocyte-derived...
View ArticleClik here to view.
Amarantus posts positive PD preclinical data with MANF
Amarantus BioScience Holdings (OTCQB:AMBS) has completed a study of MANF (mesencephalic-astrocyte-derived neurotrophic factor) administration to the putamen and the substantia nigra of pigs by...
View ArticleClik here to view.
Amarantus in capital restructuring to up-list shares
Amarantus BioSciences Holdings (OTCQB:AMBS) has implemented a 1-for-150 reverse stock split of its common stock to facilitate listing its shares on a national exchange this year. Trading on a...
View ArticleClik here to view.
Amarantus begins enrollment in PD study of eltoprazine
Amarantus BioScience Holdings (OTCQB:AMBS) has opened the first clinical trial site for enrollment for a Phase 2b study of its lead product candidate, eltoprazine, for the treatment of Parkinson’s...
View Article
